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Abstract: Over the years development of selective estrogen receptor (ER) ligands has been 
of great concern to researchers involved in the chemistry and pharmacology of anticancer 
drugs, resulting in numerous synthesized selective ER subtype inhibitors. In this work, a 
data  set  of  82  ER  ligands  with  ERα  and  ERβ  inhibitory  activities  was  built,  and 
quantitative  structure-activity  relationship  (QSAR)  methods  based  on  the  two  linear 
(multiple linear regression, MLR, partial least squares regression, PLSR) and a nonlinear 
statistical  method  (Bayesian  regularized  neural  network,  BRNN)  were  applied  to 
investigate the potential relationship of molecular structural features related to the activity 
and selectivity of these ligands. For ERα and ERβ, the performances of the MLR and 
PLSR  models  are  superior  to  the  BRNN  model,  giving  more  reasonable  statistical 
properties (ERα: for MLR, Rtr
2 = 0.72, Qte
2 = 0.63; for PLSR, Rtr
2 = 0.92, Qte
2 = 0.84. ERβ: 
for MLR, Rtr
2 = 0.75, Qte
2 = 0.75; for PLSR, Rtr
2 = 0.98, Qte
2 = 0.80). The MLR method is 
also more powerful than other two methods for generating the subtype selectivity models, 
resulting  in  Rtr
2  =  0.74  and  
Qte
2  =  0.80.  In  addition,  the  molecular  docking  method  was  also  used  to  explore  the 
possible binding modes of the ligands and a relationship between the 3D-binding modes 
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and the 2D-molecular structural features of ligands was further explored. The results show 
that the binding affinity strength for both ERα and ERβ is more correlated with the atom 
fragment type, polarity, electronegativites and hydrophobicity. The substitutent in position 
8 of the naphthalene or the quinoline plane and the space orientation of these two planes 
contribute  the  most  to  the  subtype  selectivity  on  the  basis  of  similar  hydrogen  bond 
interactions  between  binding  ligands  and  both  ER  subtypes.  The  QSAR  models  built 
together  with  the  docking  procedure  should  be  of  great  advantage  for  screening  and 
designing ER ligands with improved affinity and subtype selectivity property. 
Keywords: receptor; selectivity; QSAR; docking 
 
1. Introduction 
The estrogen receptor (ER), a member of the nuclear receptor superfamily of ligand-modulated 
transcriptional factors [1], is  responsible for transcription of genes containing  estrogen responsive 
elements or repression of some genes [2]. ER mediates the activity of estrogens in the regulation of a 
number of important physioligical processes, including the development and function of the female 
reproductive system and maintenance of bone mineral density and cardiovascular health; however 
stimulation of other tissues can increase the risk of cancer within these tissues, particular in female 
breast and uterus [3]. Thus, ER has been a target for pharmaceutical agents for hormone replacement 
in menopausal women, uterine and breast cancers.  
ER was found in two isoform subtypes, i.e., ERα and ERβ. Studies have shown the two subtypes 
have different functions and distributions in certain tissues [4,5]. Molecules that selectively activate 
ERβ  not  only  hold  promise  for  the  treatment  of  certain  cancers,  endometriosis  and  inflammatory 
diseases and cardiovascular and CNS conditions [6], but also have a profound effect in regulating brain 
development and estrogen-induced promotion of neurogenesis and memory, in conjunction with its 
reduced feminizing effects [7]. In addition, there are unexpected adverse effects of the ER ligands 
already used as clinical agents. Extensive efforts are being made to develop subtype-specific ligands 
which selectively antagonize undesirable estrogenic effects, while promoting positive estrogen effects 
for therapeutic purposes.  
The  mobility  and  plasticity  of  the  ER  ligand  binding  domain  (LBD)  allow  compounds  of 
extraordinary structural diversity mimicking natural estrogen agonists or antagonist to bind to ER 
subtypes. Remarkably, the smaller LBD volume for ERβ comparing to that for ERα and differences in 
the  amino  acids  hold  promise  of  discover  and  design  ligands  with  a  degree  of  subtype-selective 
agonist/antagonist character. Nevertheless, the similarity of the binding pocket between ERα and ERβ 
increases the difficulty of developing ligands having sufficient levels of ERβ selectivity and binding 
affinity. The key issue in the design of new selective ER ligands is to explore the properties of the 
chemical  structure  in  combination  with  its  ability  of  inducing  a  pharmacological  response  as  a 
consequence of receptor-binding. Great advances have been made in recent years because of multiple 
structurally  diverse  compounds  were  synthesized  and  have  been  shown  to  exhibit  unprecedented 
estrogen receptor subtype selectivity [8–11].  Int. J. Mol. Sci. 2010, 11                       
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Most of these synthesized compounds are based on the scaffolds of the known ER subtype selective 
compounds. However, this cannot avoid the risk that non selective or low binding affinity compounds 
will be synthesized and tested experimental, which may result in a tremendous financial cost and waste 
of time. Thus, the need for rapid and cost-effective screening tools to detect and characterize the 
agents with selective ER subtype binding affinity is urgent. Since compounds already confirmed by 
experimental  assays  provide  an  opportunity  to  understand  the  basis  of  subtype  selectivity,  the 
development of models for predicting the subtype selectivity would allow for the development of more 
potent and selective compounds for these important pharmaceutical targets. In this context, QSARs 
can be of valuable assistance in predicting the estrogenic activity of certain molecules [12].  
Numerous QSARs have been developed to predict hormone relative binding affinity and to indicate 
potential estrogenicty, such as CoMFA [13], KNN [14], HQSAR [15]. However, for studying the 
structural information relating to the binding affinity for ERα and ERβ, finding the subtype selective 
ligands with proper binding affinity, counTable QSAR models are available. Peter [16] constructed 
CoMFA models to both isoforms of the ERs. When validated by the most predictive models, the most 
selective  ligands  were  ranked  correctly.  ANNs  (artificial  neural  networks)  were  used  to  model 
selective  binding  of  48  phytoestrogens  and  structurally  related  compounds  at  ERα  and  ERβ  by 
Agatonovic-Kustrin [17] and some structural characteristics responsible for the selective binding to 
ERα  and  ERβ  were  identified.  Barrett  et  al.  [18]  synthesized  a  group  of  benzoxepin-derived  ER 
ligands and investigated the subtype selectivity using a PLS model combining different descriptors 
with the endpoint LogIC50 (ERβ/α).  
3D-QSAR  techniques  are  generally  considered  to  be  the  most  effective  means  of  predicting 
biological activity. However, they usually require an accurate superposition of structures, which has 
proven to be the major bottleneck [19,20]. Classical linear QSAR methods relay on a higher number 
and better quality of molecular descriptors that cover a broader range of structural characteristics, 
providing  an  alternative  perspective  on  the  ligand  binding  properties  of  the  ERs  that  might  be 
important for the activity [21]. Compared with the linear QSAR models, Bayesian regularized neural 
networks  (BRNNs)  have  the  advantage  of  managing  data  containing  non-linear  relationships  for 
modeling and predictive purpose avoiding the overtraining and overfitting problems that perplex the 
NN  (neural  network)  applications  in  generating  QSAR  models,  compared  with  conventional  
networks [22,23].  
The aim of this paper was to investigate the structural features contributing to the binding affinity of 
a  series  of  2-arylnaphthalene  and  2-arylquinoline  derivatives  to  ERα  and  ERβ  receptors.  More 
importantly, we are very interested in investigating the structural characteristics contributing to the 
subtype  selectivity  profile  and  to  try  to  discover  new  selective  ERβ-agonists  with  proper  binding 
affinity. To this end, MLR and PLS regression (PLSR), in combination with a Bayesian method, i.e., 
BRNN, were used for the investigation. In addition, as an alternative and supplemental approach to 
QSAR methods, Surflex-Docking procedure was undertaken, which shed further light on the QSAR 
models built and searching the putative binding modes for the screening purpose. This should be useful 
for guiding future medicinal chemistry efforts designed to discover selective ligands of ERβ having 
increased binding affinity and higher selectivity.  
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2. Material and Methods 
2.1. The Data Set 
The  data  set  used  in  the  investigation  contains  82  ER  ligands,  mainly  represented  by  
2-arylnaphthalene and 2-arylquinoline derivatives, which were collected from the literature  [9,24]. 
These compounds were designed specifically to mimic the genistein framework producing new ER 
ligands with improved binding affinity. The affinity as measured by IC50s for human ERα or ERβ of all 
the compounds was determined by a competitive radioligand binding assay [9,24]. For QSAR analysis, 
negative  logarithm  of  IC50  values,  i.e.,  pIC50  (M),  were  generated.  Further,  molecular  descriptors 
correlating  with  the  selectivity  (S)  of  binding  affinity  of  ligands  between  ERα  and  ERβ  were 
investigated, which can greatly beneficial the modulator screen and drug design. Herein we developed 
the following equation at the premise of the αIC50 is larger than βIC50 of the ligands: 
10
50 50
50
IC IC
S log
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
           (1) 
where a high S value indicates a priority to bind the LBD of ERβ. The S value increases, the selectivity 
power between the two ER subtypes increases, and when S > 1, corresponding ligands have, at least, a 
10-fold binding affinity with ERβ than ERα and are recommended for the SERM screen process.  
Detailed information of the compounds in the data set (SIMLE strings, corresponding pIC50 values for 
both ERα and ERβ, the S values) is presented in Table 1 as supplementary information. 
Table 1. The SMILEs and pIC50 information of the compounds studied herein. 
NO.  SMILES  pIC50(α)  pIC50(β)  S 
compound1  OC1=CC=C(C2=CC(F)=C(C(Cl)=C(O)C=C3)C3=C2)C=C1  6.40  7.96  1.55 
compound2  OC1=C(F)C=C(C2=CC=C(C=C(O)C=C3C#C)C3=C2)C=C1  6.14  7.92  1.78 
compound3  OC1=C(F)C=C(C2=CC=C(C=C(O)C=C3F)C3=C2)C=C1  6.68  7.82  1.11 
compound4  OC1=CC=C(C2=CC=C(C=C(O)C=C3C#N)C3=C2)C=C1  6.08  7.70  1.61 
compound5  OC1=CC(F)=C(C2=CC=C(C=C(O)C=C3C#N)C3=C2)C(F)=C1  6.35  7.66  1.29 
compound6  OC1=CC=C(C2=CC(C#N)=C(C=C(O)C=C3)C3=C2)C=C1  5.98  7.64  1.65 
compound7  OC1=CC=C(C2=CC(CC)=C(C=C(O)C=C3)C3=C2)C=C1F  5.95  7.60  1.65 
compound8  OC1=CC=C(C2=CC(C#N)=C(C=C(O)C=C3)C3=C2)C=C1F  5.68  7.57  1.89 
compound9  OC1=CC=C(C2=CC=C3C(Cl)=C(O)C=CC3=C2)C(Cl)=C1  6.44  7.48  1.00 
compound10  BrC2=CC(C3=CC=C(O)C(F)=C3)=NC1=CC=C(O)C=C12  5.55  7.47  1.92 
compound11  BrC2=CC(C3=CC=C(O)C=C3)=NC1=CC=C(O)C=C12  5.67  7.37  1.68 
compound12  ClC2=CC(C3=CC=C(O)C=C3)=NC1=CC=C(O)C=C12  5.67  7.34  1.66 
compound13  ClC2=CC(C3=CC=C(O)C(F)=C3)=NC1=CC=C(O)C=C12  5.61  7.28  1.66 
compound14  OC3=CC=C(C=C3F)C2=CC=C(C1=C2)C(C)=C(C=C1C#N)O  5.39  7.22  1.82 
compound15  OC3=CC=C(C=C3)C2=CC=C1C(F)=C(C=CC1=C2)O  6.11  7.15  1.00 
compound16  OC3=C(F)C=C(C=C3F)C2=CC=C1C=C(C=CC1=C2)O  6.04  7.08  1.00 
compound17  OC1=C(C=C(C3=CC=C2C=C(O)C=C(C2=C3)C=O)C=C1)F  6.14  7.96  1.82 
compound18  OC1=CC=C(C2=CC=C3C=C(O)C=CC3=C2)C(Cl)=C1  7.00  7.85  0.79 
compound19  OC3=CC=C(C=C3)C2=CC(F)=C1C=C(C=CC1=C2)O  6.66  7.80  1.11 
compound20  OC3=C(F)C=C(C=C3)C2=CC=C1C=C(C=C(C#N)C1=C2)O  6.02  7.68  1.65 Int. J. Mol. Sci. 2010, 11                       
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Table 1. Cont. 
NO.  SMILES  pIC50(α)  pIC50(β)  S 
compound21  OC3=CC=C(C=C3)C2=CC(Cl)=C1C=C(C=CC1=C2)O  6.52  7.64  1.08 
compound22  OC3=CC=C(C=C3F)C2=CC(CC)=C1C=C(C=CC1=C2)O  5.63  7.62  1.99 
compound23  OC3=CC=C(C=C3)C2=CC=C1C(Cl)=C(C=CC1=C2)O  6.04  7.60  1.55 
compound24  OC3=C(F)C=C(C(F)=C3)C2=CC=C1C=C(C=CC1=C2)O  6.57  7.55  0.94 
compound25  OC3=CC(F)=C(C(F)=C3)C2=CC=C1C(Cl)=C(C=CC1=C2)O  6.46  7.47  0.97 
compound26  OC3=CC=C(C=C3F)C2=CC=C1C(Cl)=C(C=CC1=C2)O  5.84  7.40  1.54 
compound27  OC3=C(F)C=C(C=C3)C2=CC=C1C(Br)=C(C=C(C#N)C1=C2)O  5.94  7.35  1.39 
compound28  OC3=CC=C(C=C3F)C2=CC=C1C=C(C=CC1=C2)O  6.04  7.30  1.24 
compound29  OC3=C(F)C=C(C=C3)C2=CC=C1C=C(C=C(C#CC)C1=C2)O  5.74  7.26  1.50 
compound30  OC3=C(F)C=C(C(F)=C3)C2=CC(C#N)=C1C=C(C=CC1=C2)O  5.73  7.16  1.41 
compound31  OC3=C(F)C=C(C=C3)C2=CC=C1C=C(C=C(C=C)C1=C2)O  5.28  7.14  1.85 
compound32  OC3=C(F)C=C(C(F)=C3)C2=CC=C1C(Cl)=C(C=CC1=C2)O  5.93  7.07  1.11 
compound33  OC3=CC=C(C(C)=C3)C2=CC=C1C=C(C=CC1=C2)O  6.40  7.00  0.48 
compound34  OC3=C(F)C=C(C=C3F)C2=CC=C1C(Cl)=C(C=CC1=C2)O  5.28  6.97  1.68 
compound35  OC3=CC=C(C=C3)C2=CC(C#N)=C1C(Br)=C(C=CC1=C2)O  5.88  6.92  1.00 
compound36  OC3=CC=C(C=C3)C2=CC=C1C=C(C=CC1=C2)O  5.68  6.79  1.08 
compound37  OC1=CC=C2C(C(C#N)=CC(C3=CC=C(O)C(F)=C3)=N2)=C1  4.98  6.64  1.65 
compound38  OC3=CC=C(C=C3Cl)C2=CC=C1C(Cl)=C(C=CC1=C2)O  5.45  6.49  1.01 
compound39  OC1=CC=C2C(C(C=C)=CC(C3=CC=C(O)C(F)=C3)=N2)=C1  5.41  6.36  0.89 
compound40  OC3=C(F)C=C(C=C3F)C2=CC(C#N)=C1C=C(C=CC1=C2)O  5.26  6.24  0.93 
compound41  OC1=CC=C2C(C(C#C)=CC(C3=CC=C(O)C=C3)=N2)=C1  4.82  6.12  1.28 
compound42  OC1=CC=C2C(C=CC(C3=CC=C(O)C=C3)=N2)=C1Br  4.94  6.06  1.08 
compound43  OC1=CC=C2C(C=CC(C3=CC=C(O)C=C3)=N2)=C1  4.75  5.77  0.97 
compound44  OC1=CC=CC2=CC(C3=CC=CC(O)=C3)=CC=C12  4.84  5.69  0.78 
compound45  OC1=CC=C2C(C(C(C)=O)=CC(C3=CC=C(O)C=C3)=N2)=C1  4.50  5.66  1.12 
compound46  OC(C=CC2=C3)=CC2=CC=C3C1=CC=CC=C1  4.87  5.43  0.41 
compound47  OC(C=CC2=C3)=CC2=C(C#CC)C=C3C1=CC=C(O)C(F)=C1  5.46  7.00  1.52 
compound48  OC(C=CC2=C3)=C(Cl)C2=C(C#N)C=C3C1=CC=C(O)C(F)=C1  5.52  6.96  1.42 
compound49  OC(C=CC2=C3)=C(Br)C2=CC=C3C1=CC=C(O)C=C1  5.58  6.89  1.29 
compound50  OC(C=CC2=C3)=C(C)C2=CC=C3C1=CC=C(O)C=C1  5.55  6.77  1.19 
compound51  OC1=CC=C2C(C=CC(C3=CC=C(O)C=C3)=N2)=C1  5.20  6.52  1.30 
compound52  OC1=CC=C2C(C(Br)=CC(C3=CC(F)=C(O)C(F)=C3)=N2)=C1  5.11  6.44  1.32 
compound53  OC1=CC=C2C(C(CC)=CC(C3=CC=C(O)C=C3)=N2)=C1  5.20  6.28  1.05 
compound54  OC1=CC=C2C(C(C=C)=CC(C3=CC=C(O)C=C3)=N2)=C1  5.30  6.22  0.87 
compound55  OC1=CC=C2C(C(CC)=CC(C3=CC=C(O)C(F)=C3)=N2)=C1  4.76  6.10  1.33 
compound56  OC(C=CC2=C3)=C(OC)C2=CC=C3C1=CC=C(O)C=C1  5.05  5.94  0.83 
compound57  OC(C=CC2=C3)=C( [N+]( [O-])=O)C2=CC=C3C1=CC=C(O)C=C1  5.15  5.70  0.41 
compound58  OC1=CC=C2C(C(C4=CC=CC=C4)=CC(C3=CC=C(O)C(F)=C3)=N2)=C1  4.74  5.68  0.88 
compound59  OC3=CC=C(C=C3)C2=CC=C1C=CC=CC1=C2  5.20  5.61  0.21 
compound60  OC1=CC(C3=CC=C2C=CC(O)=CC2=C3)=CC=C1  4.58  5.25  0.56 
compound61  OC3=CC=C(C=C3)C2=CC=C1C(C4=CC=CC=C4)=C(O)C=CC1=C2  4.91  5.13  -0.19 
compound62  OC1=CC=C2C(C(OC)=CC(C3=CC=C(O)C=C3)=N2)=C1  4.18  4.92  0.66 
compound63  OC1=CC=C2C(C(C(O)C)=CC(C3=CC=C(O)C(O)=C3)=N2)=C1  4.30  4.30  - 
--mpound64  OC3=CC=C(C(F)=C3)C2=CC=C1C(Cl)=C(O)C=CC1=C2  6.24  7.92  1.68 Int. J. Mol. Sci. 2010, 11                       
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Table 1. Cont. 
NO.  SMILES  pIC50(α)  pIC50(β)  S 
compound65  OC3=CC(F)=C(C(F)=C3)C2=CC=C1C=C(O)C=CC1=C2  6.99  7.64  0.54 
compound66  OC3=CC=C(C=C3)C2=CC=C1C(Cl)=C(O)C=C(C#N)C1=C2  6.01  7.52  1.50 
compound67  OC3=CC=C(C=C3F)C2=CC(C=C)=C1C=C(O)C=CC1=C2  5.60  7.36  1.75 
compound68  OC3=CC=C(C=C3)C2=CC(C#N)=C1C(Cl)=C(O)C=CC1=C2  5.96  7.22  1.23 
compound69  OC3=CC=C(C=C3Cl)C2=CC=C1C=C(O)C=CC1=C2  5.97  6.96  0.94 
compound70  OC3=CC=C(C(OC)=C3)C2=CC=C1C=C(O)C=CC1=C2  5.76  6.57  0.74 
compound71  OC1=CC=C2C(C(C(C)=O)=CC(C3=CC=C(O)C(F)=C3)=N2)=C1  4.47  6.03  1.55 
compound72  OC1=CC=C2C(C(C#C)=CC(C3=CC(F)=C(O)C(F)=C3)=N2)=C1  4.32  5.12  0.73 
compound73  OC(C=CC2=C3)=CC2=CC=C3C1=CC=CC=C1O  4.30  4.70  0.18 
compound74  OC(C=CC2=C3)=CC2=CC=C3C1=CC=C(O)C=C1F  6.62  7.70  1.04 
compound75  OC(C=C(CC)C2=C3)=CC2=CC=C3C1=CC(F)=C(O)C=C1  5.95  7.60  1.65 
compound76  OC(C=CC2=C3)=CC2=C(C=O)C=C3C1=CC=C(O)C(F)=C1  5.64  7.47  1.83 
compound77  OC(C=CC2=C3)=C(F)C2=C(C#N)C=C3C1=CC=C(O)C(F)=C1  5.51  7.25  1.74 
compound78  OC(C=CC2=C3)=CC2=C(C#C)C=C3C1=CC=C(O)C(F)=C1  5.61  7.20  1.58 
compound79  OC(C=CC2=C3)=C(Cl)C2=CC=C3C1=CC=C(O)C=C1C  6.40  6.89  0.32 
compound80  OC1=CC=C2C(C(C#N)=CC(C3=CC=C(O)C=C3)=N2)=C1  5.34  6.55  1.18 
compound81  OC1=CC2=CC(C3=CC=CC=C3)=CC=C2C=C1  4.47  5.28  0.74 
compound82  OC1=CC(O)=CC2=C1C(C(C3=CC=C(O)C=C3)=CO2)=O  5.40  7.01  1.60 
2.2. Molecular Descriptors 
The  molecular  descriptors  were  calculated  with  the  DRAGON  program  packages  which  were 
originally  developed  by  the  Milano  Chemometrics  and  QSAR  Research  Group 
(www.disat.unimib.it/chm/).  DRAGON  provides  more  than  1,600  molecular  descriptors  that  are 
divided into 20 logical blocks, which contain not only the simplest atom type, functional group and 
fragment counts, but also several topological and geometrical descriptors. Some molecular properties 
such  as  logP,  molar  refractivity,  and  number  of  rotaTable  bonds,  H-donors,  H-acceptors,  and 
topological  surface  area  (TPSA)  are  also  calculated.  According  to  the  energy  minimized  3D 
conformation  of  each  compound,  1,664  2D  and  3D  molecular  descriptors  were  computed  with 
DRAGON packages based on the structure of a compound. Constant or near constant values and 
descriptors with zero standard deviations were excluded in order to reduce redundant and non useful 
information. Finally 1,333 DRAGON descriptors were retained.  
2.3. Statistical Methods  
For data analysis and modeling, multiple Linear Regression (MLR), partial least squares regression 
(PLSR)  and  Bayesian  regularized  neural  network  (BRNN)  investigations  were  performed.  MLR 
attempts to model the relationship between two or more explanatory variables and a response variable 
by  fitting  a  linear  equation  to  the  observed  was  employed  to  correlate  the  binding  affinity  and 
molecular descriptors. This method has been widely applied in many QSAR studies, and has proven to 
be a useful linear regression method to build QSAR models that may explore straightforward the 
properties of the chemical structure in combination with its ability of inducing a pharmacological Int. J. Mol. Sci. 2010, 11                       
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response  [25].  In  the  procedure,  stepwise  method  was  introduced  to  extract  the  most  correlate 
descriptors.  
PLSR is a statistical method that bears some relation to principal components regression; instead of 
finding hyperplanes of maximum variance between the response and independent variables, it finds a 
linear regression model by projecting the predicted variables and the observable variables to a new 
space and is used to find the fundamental relations between two matrices (X and Y), i.e., a latent 
variable approach to modeling the covariance structures in these two spaces. A PLS model will try to 
find  the  multidimensional  direction  in  the  X  space  that  explains  the  maximum  multidimensional 
variance direction in the Y space. PLS-regression is particularly suited when the matrix of predictors 
has  more  variables  than  observations,  and  when  there  is  multi-collinearity  among  X  values.  The 
detailed algorithm of this method can refer [26,27].  
Backpropagated artificial neural networks (ANNs) have been widely used for molecular modeling 
due  to  their  computational  efficiency  and  their  ability  for  approximating  any  mapping  between 
independent and response variables. However, their inherent unstability and the existence of overfitted 
solutions  increase  when  the  number  of  parameters  is  increased  [28].  The  Bayesian  regularization 
overcomes the deficiencies of ANNs by modifying the ANNs performance. The Bayesian framework 
deals  with  uncertainly  by  applying  probabilities  to  each  possible  event  [29,30].  In  contrast  to 
conventional  network  training,  where  an  optimal  set  of  weight  is  chosen  by  minimizing  an  error 
function, Bayesion approach involves a probability distribution of the network weight. After the data is 
taken, the density function for the weights can be updated according to Bayes’ rule: 
     
 
, , ,
, , ,
,,
P D M P M
P D M
P D M
   
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          (2) 
where D is the data set, M is the particular neural network model used and ω is the vector of net work 
weights. P(ω|D,α,β,M) is the posterior probability, that is the plausibility of a weight distribution 
considering the information of the data set used. P(ω|D,α,M) is the prior density, which represents our 
knowledge of the weights before any data are collected. P(D|ω,β,M) is the probability of the data 
occurring, given the weights. P(D|α,β,M) is a normalization factor, which guarantees that the total 
probability is 1. Gauss-Newton approximation [31] to Hessian matrix of the objective function F(ω) 
has been developed to effectively calculate the regularization. Bayesian methods produce predictors 
that are robust and well matched to the data which make optimal predictions. 
In  this  work,  two-layer  networks  were  fully  connected,  with  a  hyperbolic  tangent  function 
employed  in  the  hidden  layer  and  a  linear  transfer  function  in  the  output  layer.  The  Levenberg-
Marquardt training algorithm [32] was introduced to accelerate the convergence of the targets. The 
starting-values for the BRNN model parameters were selected according to Nguyen-Widrow rules 
[33]. The training is stopped at the maximum of the evidence for the hyperparameters α and β [34].  
2.4. Construction of Training and Test Set 
As external validation can provide a more rigorous evaluation of a model's predictive capability for 
untested  chemicals,  the  best  proof  of  an  already  developed  model’s  accuracy  is  to  test  model 
performance on these additional data. For this purpose, before the models were built the whole data set Int. J. Mol. Sci. 2010, 11                       
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was split into two subsets, i.e., the training set used to build the model and the independent test set to 
validate the model's accuracy. In this investigation, we performed this splitting on the basis of their 
distribution in the chemical space which is defined by the Kohonen neural network [35].  
A self-organizing map (SOM) creates a set of prototype vectors representing the dataset and carries 
out a topology preserving projection of the prototypes form the d-dimensional grid. This grid is a 
convenient visualization space for showing the cluster structure of the data. Thus, similar objects were 
mapped into the same position(x, y coordinates in a Kohonen map). In this work, only a part of 
representative object form each position in the map was chosen for the training set, respecting the 
original proportion among the different classes.  
2.5. Docking 
Structurally, the C-terminal LBD of the ERs forms a 3D wedge-shaped binding pocket composed of 
non-polar residues in the active site, resulting in a largely hydrophobic pocket. This pocket displays 
specific binding features, allowing it to accommodate a varied set of steroid-like ligands. Basically, we 
believe that a compound enters the active site of ER in a penetration manner, since this pocket is a 
narrow-long channel with different hydrophobicity in the two terminals of the channel. Therefore, a 
hydrophobic compound with different structural ends revealing the hydrophobic variations can easily 
penetrate into the pocket and bind to a hydrophobic area in the protein [36]. The mechanism might 
explain the binding characteristics of most ligands in the ER ligand binding domain. In this work, in 
order to probe the possible binding conformations of ligands in the ER LBD and further rationalize ER 
subtype selectivity of these compounds, a molecular docking method was also employed.  
Surflex-Dock docks ligands automatically into a receptor’s ligand binding cavity using a protomol-
based method and an empirically derived scoring function. The protomol is a unique and important 
factor of the docking algorithm and is a computational representation of assumed ligands that interact 
with the binding cavity. In addition to the automated docking process, the function in Surflex-Dock 
has been improved by incorporating a base portion matching algorithm that allows a fragment of the 
ligand to be prepositioned as it docks in the binding site. The scoring function based on the binding 
affinities  of  protein-ligand  complexes  and  on  their  X-ray  structures  contains  hydrophobic,  polar, 
repulsive, entropic and solvation terms [37,38]. The Cscore functions are also available in the Sybyl  
software package.  
Crystal  structures  of  human  ERα  and  ERβ  with  same  ligands  co-crystallized  can  enhance  the 
accuracy  when  comparing  a  ligand  docking  poses  in  ERα  and  ERβ.  In  this  work,  six  ligand-  
co-crystallized ER structures were used and the X-ray crystallographic data were retrieved from the 
Protein Data Bank (PDB ID 1X7R and 1X7E for ERα; 1QKM, 1X78, 1YYE and 1YY4 for ERβ). As 
listed in Table 2, 1X7R and 1QKM, 1X7E and 1X78 have the same co-crystallized ligands. 1YYE and 
1YY4 were chosen because the co-crystallized ligands are also within the studied compound sets 
(compound6 and compound23).  
Prior to docking, in the protein preparation procedure all waters were removed and the hydrogen 
atoms were added in predicted models using the Biopolymer module in a random way. Protomol for 
Surflex-Dock  was  generated  according  to  the  software  protocol.  Two  important  factors  bloat  and 
threshold that can significantly affect the size and extent of the protomol were adjusted in order to get Int. J. Mol. Sci. 2010, 11                       
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the best docking results. For 1X7R, 1QKM, 1X78, 1YYE and 1YY4, bloat was set to 0.0 and threshold 
was set to  0.50. For  1X7E, these  parameters  were  set to 0.0 (bloat) and 0.70 (threshold). Before 
employed  to  the  docking  stimulation,  all  the ligands  were  energetically  minimized  employing  the 
Tripos force field and Gasteiger-Huckel charges. Besides, other parameters with default setting and 
Cscore functions were employed in all runs.  
Table 2. The crystals used in the docking process and 2D structures of their co-crystallized 
ligand. 
Crystal  ligand  Crystal  ligand 
1X7R 
 
1QKM 
 
1X7E 
 
1X78 
 
1YYE 
 
1YY4 
 
3. Results 
Self-organizing  maps  are  a  special  kind  of  neural  network  that  can  be  used  for  clustering, 
visualization  and  abstraction  tasks.  SOM  is  especially  suitable  for  data  surveys  because  of  its 
prominent  visualization  properties.  We  used  a  small  Kohonen  network  with  5  ×   5  =  25  neurons 
producing a map with 25 points for the ERα and ERβ sets, while for the Selectivity set, a map with  
4 ×  4 = 16 points was applied. The SOM built for all the data sets is shown in Figure 1. Compounds in 
the training and test sets, as well as the validation sets for the BRNN models are clearly marked. 
Figure 1. The distribution the 82 compounds in the 5 ×  5 top-map of the Kohonen neural 
network: (A) is for the ERα set and (B)  is for the ERβ set. (C)  is the distribution of  
81 compounds in the 4 ×  4 top-map Kohonen neural network for the Selectivity set. Those 
numbers with grey circle background are compounds of the test set, while the others are 
the ones of the training set. Numbers in blue rectangles are compounds further split for the 
validation of the BRNN models. 
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Figure 1. Cont. 
 
 
3.1. ERα 
3.1.1. MLR 
A stepwise MLR method was employed to extract the descriptors most correlated with the relative 
bioactivity and the following optimal MLR model was arrived at: 
     
   
50 2 181 0 996 44 287 11 238
0 397 0 090 96
pIC . . . . JGI10-9.883 2.266 E1p
+2.998 . R4u-0.577 . BELTA
      
       
(3) 
ntr = 61, nte = 21, R
2 = 0.72, SEE = 0.36, F = 36.01, Q
2 = 0.63, SEP = 0.44 
where, ntr and nte are the number of compounds in the training set and the test set, respectively. R
2 is 
the conventional correlation coefficient; Q
2 is the external-validated correlation coefficient; F is the  
F-test value; SEE is the standard error of estimation for the training set; SEP is the standard error of 
prediction for independent test set. The experimental pIC50 values versus predicted pIC50 values are 
shown in Figure 2(A). From the figure, we can get the information the predicted pIC50 values for most 
of the compounds are well consistent with the experimental results, indicating the good performance of 
the built MLR model. Int. J. Mol. Sci. 2010, 11                       
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Figure 2. Experimental vs predicted pIC50 values of ligands for the ER alpha (left), ER 
beta (middle) and experimental vs predicted S values of ligands for Selectivity (right) by 
the MLR models (A) for the training and test sets, by the PLSR models (the pIC50 and 
descriptor  values  were  normalized)  (B).  (C)  Experimental  and  predicted  values  by 
Baysian-regularized neural network for the training, validation and independent test sets 
for  ER  alpha  (left),  ER  beta  (middle),  and  the  Selectivity  (right).  The  empty  circles 
represent the outliers present. 
 
3.1.2. PLSR  
PLSR is based on linear transition from a larger number of original descriptors to a small number of 
orthogonal factors (latent variables) providing the optimal linear model in terms of predictivity [3440]. 
All the variables were normalized before the PLSR procedure was taken by x = [x – mea (x)]/std(x). Int. J. Mol. Sci. 2010, 11                       
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Herein x represents a variable and std(x) is the standard deviation. The resultant PLSR model with six 
latent variables outweighs others as shown in Figure 3(A). The corresponding statistical correlation 
coefficients  (Rtr
2  and  Qte
2)  are  0.92  and  0.84  respectively  for  the  training  and  test  set;  while  the  
Leave-One-Out  (LOO)  cross-validated  coefficient  of  determination  Qcv
2  is  0.43.  And  the 
corresponding standard error is 0.28 for the model built and 0.44 for independent test data. The 6 latent 
factors totally explained 63.87% of the independent variances and 92.08% of the dependent variance. 
According to the Variable Importance in Projection (VIP), which summarizes the importance of X 
variables in the model, R4u, R4e, R5e, HATS5e, nPyridines, C-028, N-075, E1v, JGI10, E1p, R1e
+ 
and  RTe
+  are  ones  among  the  most  relevant  descriptors.  The  experimental  (normalized)  versus 
predicted  pIC50  values  for  both  training  and  test  sets  were  plotted  in  Figure  2(B).  The  model’s 
performance is good as most of the compounds are well distributed along the trend line. 
Figure 3. Trend of the statistical results of the PLSR models with vary latent factors based 
on the data sets for ER alpha (A), ER beta (B) and Selectivity (C).  
 
3.1.3. BRNN 
The 61 compounds in the training set for the MLR and PLS models were further randomly split into 
one training set and one validation set with a ratio of 2:1 (Figure 1) for building the BRNN models. 
The simulation was iterated 50 times and the average predictive values were taken as the final result, 
in order to minimize the differences and random error. The optimal PCA-BRNN model has five hidden 
neurons,  using  five  input  neurons  for  the  PCs,  as  displayed  in  Figure  2(C),  with  the  statistical 
coefficient Rtraining is 0.87, Rvalidation is 0.76 and Rtest is 0.73, while the sse(sum squared error) are 0.19, 
0.09 and 0.10, for the training, internal validation and independent test sets, respectively. Int. J. Mol. Sci. 2010, 11                       
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3.1.4. Surflex-Docking 
We implemented the docking process with prior minimized ligands and X-ray crystallographic data 
1X7R  and  1X7E  retrieved  from  PDB.  After  running  the  Surflex-Dock,  the  scores  of  10  docked 
conformers  were  ranked  in  a  molecular spreadsheet. The crystallized  ER structures  with  different 
resolutions and binding ligands greatly impact the docking accuracy and poses ranking. No precise 
correlation  could  be  found  between  the  top  rank  docking  poses  scores  and  pIC50  values  when 
employing these two crystallized ER structures as the pIC50 values relate to number of events. In this 
study,  we  also  docked  the  compounds  into  the  crystallographic  protein  structures  without  water 
removing  and  no  significant  difference  presents.  In  order  to  illustrate  the  interaction  mechanism, 
compound18,  the  most  potent  ERα  ligand  among  the  82  compounds,  for  more  detailed  analysis.  
Figure 4 generally represents the interacting model of compound18 with ERα when docked into 1X7R  
and 1X7E.  
Figure 4. (A) Superpositon of Docking conformations of Compound 18 in 1X7R (green) 
and  1X7E  (cyans).The  interacting  modes  of  compound18  with  1X7R  (B)  and  1X7E  
(C). Compound18 and the important residues for binding interaction are represented by 
stick and line models, respectively. The magentas dash lines denote the hydrogen bonds. 
 
 
The binding conformation docked in the two crystal ERα structures are almost at the same position 
in the active site [Figure 4(A)] with the chloro substituent directing towards the hydrophobic group of 
PHE404, PHE425 and LEU346. As previous work proved, the hydroxyl of the phenyl ring has a  
H-bond with GLU353 and ARG394, and the hydroxyl of the naphthyl moiety may form a H-bond with 
HIS524 [9]. However, in our work, GlY521 and LEU525 can also form H-bond interactions with 
compound18, as shown in Figure 4(B),(C).  Int. J. Mol. Sci. 2010, 11                       
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These H-bonds form the basis of the favorable binding interaction of the ligand with ERα. Still, the 
interactions caused by lipophilic features of the molecules play an important role in determining the 
binding affinity since a linear correlation between the ClogP and pIC50 was attained for these studied 
compounds (R = 0.32). Notably, the docking conformations of compound18 are totally different from 
the compounds bound to 1X7R and 1X7E (Table 2), as shown by their structural skeletons in the two 
X-ray structures. The binding orientations are different, but the H-bonding which plays a key role in 
the ligand-enzyme interaction are similar, i.e., two similar H-bonds formed between the ligand with 
HIS524,  GLU353  or  ARG394.  Therefore,  the  predicted  conformation  by  this  Docking  method  is 
reasonable.  
3.2. ERβ 
3.2.1. MLR 
Herein five descriptors were extracted, and with which the most predicative MLR models was built 
as shown below: 
     
     
50 41 527 5 532 47 096 16 457 10 19 060 3 445 1
10 963 1 742 6 0 592 0 159 09 0 585 0 057
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. . BEHe . . EEig x . . nCb
       
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   (4) 
ntr = 61, nte = 21, R
2 = 0.75, SEE = 0.46, F = 32.35, Q
2 = 0.75, SEP = 0.46 
Figure 2(A) shows the regression plot of experimental vs predicted pIC50 values of the compounds. 
All compounds in the test set are well distributed among the training ones, indicating the high quality 
of this model.  
3.2.2. PLSR 
The  optimal  PLSR  model  was  selected  with  seven  latent  factors,  as  shown  in  Figure  3(B) 
considering  the  reliability  and  predictive  power,  and  totally  explained  66.28%  of the  independent 
descriptors and 97.78% of the dependent variables. A plot of the experimental (normalized) versus 
predicted pIC50 values is shown in Figure 2(B); all the training compounds are well distributed along 
the trend line indicating its good performance (Rtr
2 is 0.98, SEE is 0.15, LOO Qcv
2 is 0.28). When 
extrapolated to the test set, two compounds (compound44 and compound 61, marked as blue circles) 
were out of the application domain of the model. For the rest test set, the predictive capability is 
convincing, with Qte
2 is 0.80 and SEP is 0.43. The importance of each descriptor was evaluated by VIP 
and the most relevant variables are nCb-, SP20, DP20, SP19, DP19, SP18, DP18, E1v, E1p, SP17, 
DP17, R4v, PJI2, nPyridines. 
3.2.3. BRNN 
Same strategy was taken for the ERβ data set just as for the ERα data sets. Figure 2(C) presents the 
optimal BRNN models with five hidden neurons and 11 input neurons for PCs. The statistical results 
of  the  BRNN  model  are  Rtraining  is  0.91,  Rvalidation is  0.70  and  Rtest  =  0.74  with  SSEtraining  is  0.29, 
SSEvalidation is 0.14 with SSEtest is 0.15. No obvious overfitting can be observed from the model, and no Int. J. Mol. Sci. 2010, 11                       
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outliers were considered. This suggests that the BRNN model can be applied to compensate for the 
deficiency of the linear models. 
3.2.4. Surflex-Dock 
Multiple crystals  publicly available from the PDB were  obtained and the binding mode of the 
studied  compounds  were  generated  in  four  crystals  (1QKM,  1X78,  1YY4  and  1YYE).  All  the 
parameters were set as the default values in the whole process. The function scores were used to 
evaluate the binding qualities. Notably, docking into different crystal ERβ can have drastic effects on 
the ranking poses and relating scores. The first ranking pose scores failed to correlate pIC50 values 
precisely in  each condition. The performance of docking for virtual screening and binding model 
investigation  study  should  be  cautiously  analyzed.  Figure  5  shows  the  putative  binding  mode  of 
compound 17, the most potent ERβ ligand according to the experimental results, within the ligand 
binding pocket of the LBD of ERβ employing different crystal structures.  
Figure 5. Compound17 and the potent interacting residues docking into 1QKM, 1X78, 
1YY4  and  1YYE  in  sequence  (A–D).  The  magenta  dashed  lines  denote  the  
hydrogen bonds. 
 
The main variation of the binding conformation is focused on the orientations of the formyl group 
attaching to the naphthyl part and the fluoro group attaching to the phenyl part. In the docking pose in 
1QKM  and  1YY4,  the  fluoro  directs  at  MET340  and  LEU343,  while  in  1X78  and  1YYE,  the 
orientation of the phenyl group flipped and the fluoro substituent directs towards GLU305 and PHE 
356. This further result in LEU339 instead of GLU305 forming a favorable H-bond with the hydroxyl Int. J. Mol. Sci. 2010, 11                       
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group attaching to the phenyl part. Because of the flexibility of the rotaTable bond, the oxygen atom of 
formyl group orients obviously different. The docking conformations in 1YYE and 1YY4 indicate 
electrostatic interaction between the acyl of LEU298 and formyl group of compound17. While docking 
in 1QKM and 1X78, the formyl group is directed at MET336, ILE373 and ILE376. 
3.3. Selectivity 
Except for compound63 which showed the same binding affinity for both subtypes, the rest of the 
ligands studied herein tend to experimentally bind more in the LBD of ERβ. In order to study the 
contributing  structural  information,  we  defined  the  selectivity  of  binding  affinity  as  showen  by 
Equation 1 and developed MLR PLSR and BRNN models on the basis of compound 63 being excluded 
from the data set. 
3.3.1. MLR 
A MLR model with R
2 is 0.74 and SEE is 0.25 was reached (F = 25.56). When validated externally, 
the  model  well  predicts  all  the  compounds  in  the  test  set  with  Q
2  is  0.80  and  SEP  is  0.21.  Six 
molecular descriptors mostly correlating to the binding affinity property was selected as shown in 
Equation 5: 
     
   
 
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    
  
   (5) 
A plot of the experimental and predicted pIC50 values is shown in Figure 2(A). The S value mainly 
ranges from 0 to 2. If S is zero the affinity capability of the corresponding compound for ERβ will be 
two-fold of that for ERα. Its increase strengthens the Selectivity between the two subtypes remarkably. 
Compounds gathered at the right top corner have strongest binding affinity to ERβ than to ERα. These 
are SERMs for ERβ that can be further studied and screened for drug design purposes. 
3.3.2. PLSR 
A predictive QSAR model was produced using PLSR analysis to correlate variation in selective 
activity with variation in the descriptors. The optimum number of latent factors (six) corresponds to 
the  highest  correlation  coefficient  (R
2  =  0.89)  with  the  standard  error  of  prediction  is  0.35  
[Figure 3(C)], while for LOO cross-validation, the correlation coefficient Qcv
2 is 0.37. The predictive 
power  was  evalued  by  an  independent  test  set.  Compound18  and  compound82  (genistein)  were 
removed as outliers resulting in an improvement of Qte
2 from 0.50 to 0.65 with a standard error of 
0.61. The plot of experimental (normalized) and predicted S values for all compounds is shown in  
Figure 2(B). For the outliers (marked as blue circles) the predicted values are much lower than the 
experimental results. 
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3.3.3. BRNN 
The  optimal  BRNN  model  has  five  hidden  neurons,  with  14  input  neurons  for  PCs.  The 
performance of the BRNN model is not as good as that of the MLR and PLSR models and one outlier 
(compound57) was omitted from the validation set. For the training and test sets the conventional 
coefficients are 0.81 and 0.77, while for the validation set the cross-validation coefficient is 0.41. The 
resulting  graphic  model  is  provided  in  Figure  2(C).  Compound57,  marked  with  a  blue  circle,  is 
obviously far away from the trend line and badly predicted. For all the BRNN models built for ERα, 
ERβ and Selectivity, the statistical results are summarized in Table 3.  
Table 3. The statistical results of the BRNN models. 
Data set  A*  B  Rtraining  Rvalidation  Rtest  SSEtraining  SSEvalidation  SSEtest 
alpha  5  5  0.87  0.76  0.73  0.19  0.09  0.10 
beta  5  11  0.91  0.70  0.74  0.29  0.14  0.15 
Selectivity  5  14  0.81  0.65  0.77  0.009  0.005  0.005 
* A: represents the number of hidden neurons. B: represents the number of input neurons for PCs. 
SSE is abbreviation of Sum Squared error. 
3.3.4. Docking Study 
As mentioned above, no precise correlation could be found between pIC50 values and the first rank 
docking  pose  scores.  It  is  not  rational  to  investigate  the  ER  subtype  selectivity  according  to  the 
docking rank pose scores. However, comparing the docking binding conformations could shed light on 
the possible contributing molecular properties that determining the Selectivity. Herein, we compared 
the  binding  conformations  of  compound22  and  compound10  that  have  the  highest  ERβ  subtype 
selectivity docked in 1X7R(ERα) vs. 1QKM(ERβ) and 1X78ERβ) vs. 1X7E(α). 
Analysis of the X-ray co-crystal structures of ERα and ERβ complex with agonists illustrates that 
only two residue substitutions within 5Å expand the binding ligand: Met336 in ERβ replaces Leu 384 
in ERα and Ile373 replaces Met421 [39]. However, orientation and conformations of the amino acids 
could obviously vary, such as ILE424 of crystal 1X7R and ILE376 shown in Figure 6(A). Similar  
H-bond interactions were found as docking in the ERα and ERβ crystals for the compounds studied. 
For some compounds HIS521 of ERα or HIS472 of ERβ could form H-bonds with the hydroxyl group 
of the naphthyl plane. However, this determines little in the binding affinity. We speculate that the  
H-bonding  interaction  is  not  the  key  factor  determining  the  high  selectivity  between  these  two  
ER subtypes.  
The most apparent difference when docking into ERα and ERβ is the naphthalene or the quinoline 
plane. The phenyl plane is inclined to adapt a similar space orientation and position in each crystal. 
The 8-ethyl substituent of compound22 and the 8-bromo substituent of compound10 directed towards 
ERβ Ile373 docking in 1QKM and 1X78, while docking into 1X7R and1X7E the 8-ethyl substituent of 
compound22  orients  to  Met421  or  is  rotated  toward  LEU384  and  the  8-bromo  substituent  of 
compound10 was directed towards Met421 (Figure 6). These differences may explained by a favorable 
dispersive  interaction  with  ERβ  Ile373,  relative  to  a  less  favorable  interaction  with  ERα  Met421 
because of steric constraints of the ethyl group and the protein, or both. The importance of Met336 has Int. J. Mol. Sci. 2010, 11                       
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been  highlighted  in  determining  the  ERβ  selectivity  by  other  works  [9,39,40].  These  docking 
conformations of both compound22 and compound10 take the strategy that the naphthalene or the 
quinoline plane more apart from the Met336 than Leu384. Thus, we speculate that the naphthalene or 
the quinoline plane and the substituent in position 8 instead the hydrogen bond forms the most ER 
subtype selective pharmacophore. 
Figure  6.  (A)  Overlay  of  binding  conformations  of  compound10  docking  into 
1QKM(ERβ) vs. 1X7R(ERα) (left) and 1X78(ERβ) vs. 1X7E(ERα) (right). (B) Overlay of 
binding conformations of compound22 docking into 1QKM(ERβ) vs. 1X7R(ERα) (left) 
and 1X78(ERβ) vs. 1X7E(ERα) (right). 1QKM and 1X78 were colored green, while 1X7R 
and1X7E colored cyan. The magenta dashed lines denote the hydrogen bonds. 
 
4. Discussion 
4.1 ERα Models 
The MLR model was built with four descriptors. JGI10 is the mean topological charge index of 
order10, and the most important descriptors extracted that positively correlate with the binding affinity 
to ERα, which indicates the critical role of the overall charge dispersionh profile due to the influence 
of size and shape. E1p represents the 1st component accessibility directional WHIM index weighted 
by atomic polarizabilities. The atomic polarizability negatively contributes to the binding affinity. R4u, 
a GETAWAY descriptor, represents R autocorrelation of lag 4 (unweighted), demonstrates the positive Int. J. Mol. Sci. 2010, 11                       
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effect of the molecule geometry and size and shape properties. BLTA96 is Verhaal model of algae 
base-line toxicity from MLOGP relating to the bind affinity of the lipotropism. 
The PLSR model was built with six latent factors and successfully extrapolated to the independent 
test set. Thus, it can be used to further screen and discover new ERα ligands. According to the most 
important descriptors determined by VIP related to the MLR model, the importance of atom–centred 
fragment types, interatomic distances and the shape of molecule with polarity and electronegativites 
are  highlighted.  The  nitrogen  of  the  quinoline  and  pyridine  plane  is  a  characteristic  atom  type 
correlating to the binding affinity to ERα. 
The  BRNN  model  was  introduced  as  neural  nets  have  the  advantage  of  being  able  to  explore 
nonlinear relationships between dependent and independent variables, even without prior knowledge 
of the form of the nonlinearity. In order to reduce the descriptor space and the chance of correlation 
among descriptors a principal component analysis was performed before the variables were used as the 
BRNN input data. The performance of the BRNN model compared to the MLR and PLSR models is 
not that good. The increasing PCs or hidden neurons did not improve the model quality inappreciably.  
Comparing  the models  built,  The PLSR model outperformed  the others. The MLR model also 
successfully extrapolates to the independent test set. Here we recommend they could be applied to 
virtual screening of novel ERα ligands with improved affinity simultaneously to improve the accuracy. 
4.2. ERβ Models 
Five descriptors were selected for the MLR model built in this study. JGI10, the most positive 
correlated descriptor together with E1p, the most negative correlated descriptor, contributes to binding 
affinity to both ER alpha and beta isoforms. Another three descriptors correlate distinctively with the 
pIC50  for  the  ERβ:  BEHe6  is  the  highest  eigenvalue  no.  6  of  Burden  matrix  weighted  atomic 
Sanderson electronegativities. nCb- is the number of substituted benzene. EEig09x is the eigenvalue09 
from edges adjacency matrix weighted by edge degrees. These descriptors emphasize the importance 
of the molecule component structure characteristic.  
Although  two  outliers  (compound44  and  compound61)  were  omitted  when  evaluated  by  the 
independent  test  set,  the  performance  of  the  PLSR  model  is  still  considerable,  with  most  of  the 
compounds being tightly center around the trend line as shown in Figure 2(B). According to the VIP, 
the 10 most correlated descriptors mainly belong to Randic molecular profiles and most relate to the 
global molecular 3D structures and shape profile determined by atoms on molecular periphery, WHIM 
descriptors  that  elate  to  structure-property  correlations  atom-centred  fragments,  functional  group 
counts and GETAWAY descriptors that are based on the row sums of the influence(distance)matrix. 
This indicates the importance of atom types of molecules and atoms on the molecular periphery, the 
distance between atom pairs and the electrotopological state of the functional group.  
Compared with the MLR and PLSR models the BRNN model is not as powerful. 11 input neurons 
for PCs and five hidden neurons were used. For the test set compounds, the compounds are more 
dispersed from the trend line compared with the training and validation sets. 
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4.3. Selectivity Models 
A total of 81 compounds were studied with the QSAR models. The optimal MLR model arrived at 
six  descriptors:  BEHe6,  BEHm5  (highest  eigenvalue  n.  5  of  Burden  matrix  weighted  by  atomic 
masses),  EEig03r  (eigenvalue  03  from  edge  adj.  matrix  weighted  by  resonance  integrals),  DISPe  
(d  COMMA2  value  weighted  by  atomic  Sanderson  electronegativities),  CIC2  [complementary 
information content (neighborhood symmetry of 2-order)]. The graphical results visually indicate the 
performance of the PLSR model is comparable to that of the MLR model with six latent factors. The 
correlated descriptors determined by VIP give a deeper insight into the structural parameters which 
influence  the  pIC50  based  ER  subtype  selectivity  in  comparison  to  the  MLR  model,  RDF015m, 
BEHm6, H5p, E1p, RDF015e, nDB, HGM, BEHp8, L1m, H5v stress the importance of topological 
information and 3-D profiles, as well as the atom types and number of double bonds. Their definitions 
of all the descriptors can be found in the Dragon user manual and for the calculation details readers 
can refer to the Handbook of Molecule Descriptors [41]. 
One outlier (compound57) was detected in the validation set. However, its removal did not improve 
the predictive quality of the BRNN models when evaluated by the test set. Considering more input 
neurons for pcs and low Qvalidation., the BRNN failed to that accurately predict the Selectivity with the 
Dragon descriptors compared with the MLR and PLSR models, which would be of great help in 
screening ER subtype selective ligands.  
4.4. The Docking Study 
Docking method is an alternate to QSAR study in the drug screen and design procedure to discover 
and optimizing new ligands by predicting binding models and affinities of small ligands to biologically 
relevant target proteins. In this work, the Surflex docking method was implemented to understand the 
pharmacological preferences from the set of 2-arylnaphthalene and 2-arylquinoline derivatives. As a 
validation of the accuracy of the docking process, the RMSD of the crystal binding ligands from the 
crystals were compared with the top 10 ranked conformations redocked with Surflex-Dock. Before 
redocking, the ligands were minimized just like all the compounds studied. The results are summarized 
in Table 4.  
Each of the energy minimized ligand exists 10 most possible conformations docked into the binding 
pocket of the ER crystals. The top ranked conformations corresponding Surflex Scores do not show 
precise correlation with pIC50 values. Besides the complexity of the pIC50 determinant factors, the 
binding conformation is influenced by multiple factors. Mikelos [42] has pointed out that the docking 
scores are highly sensitive to the source of ligand input conformations as small changes in the ligand 
input conformation can lead to large differences of the resulting docked poses. The energy minimized 
conformations were employed because the good performance of previous works studying QSAR and 
docking  [40,43–46].  Differences  between  co-crystallized  ligand  proteins  also  lead  to  a  large 
perturbation of the resulting docking performance as demonstrated by our study results above. It has 
been suggested that consensus scoring improves the enrichment of true positives. 
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Table 4. Summary of the RMSD information when the cocrystalized ligand redocked into 
the corresponding crystals. 
Crystal  AVG_RMSD  SD_RMSD  MAX_RMSD/NO. of pose  MIN_RMSD/NO. of pose 
1X7R  0.66  0.18  0.94/7
th*  0.46/10
th 
1X7E  0.32  0.03  0.36/9
th, 10
th  0.27/5
th 
1QKM  0.39  0.06  0.47/1
th, 3
th  0.32/8
th 
1X78  0.53  0.32  1.04/5
th,7
th  0.14/1
th 
1YY4  0.63  0.30  1.01/7
th  0.14/6
th 
1YYE  0.77  0.54  1.81/7
th  0.34/1
th 
* The numbers here match along with the ten plausible poses ranking with the docking score 
descending order. 
However, this must be on the base that each individual scoring function is distinct and has relatively 
high  quality  [47].  It  is  unclear  how  the  best  docking  pose  could  be  selected.  This  results  in  the 
difficulty of using the Cscores to rank the docked poses. The highest Surflex-Dock scoring solution is 
supposed to be nearest to the experimental structure, but the RMSD analysis in Table 4 shows that the 
top ranking pose is not always the case. We suggest that the docking process used to screen and design 
the  positive  ER  ligands  with  2-arylnaphthalene  and  2-arylquinoline  scaffolds  employ  multiple 
crystallographic proteins, if available, and the results be comprehensively analyzed for each solution to 
greatly improve the accuracy. For example, in the docking of compound17 into 1YY4 in Figure 5, the 
top ranking pose confronts steric conflict as the fluoro group penetyrates into the protein too much, 
resulting in direct contact with LEU343. More importantly, the docking positive compounds should be 
further studied with the robust QSAR models in order to screen out the possible outliers and false 
positive compounds  
5. Conclusions  
This work has focused on the use of QSAR models and a docking program to study the molecular 
profiles  most  correlated  with  the  binding  affinity  of  estrogenic  ligands  and  the  origin  of  the  ER 
subtype binding selectivity. MLR, PLSR and BRNN models were built respectively for the binding 
data for ERα and ERβ and the selectivity between ER subtypes via introduction of the S (selectivity) 
dependent endpoint. All the models were tested by an independent test set, which was not used for 
building the models for their prediction capability. JGI10 and E1p are the most correlated descriptors 
to binding affinity to both ER subtypes, while BEHe6, BEHm5 and EEig03r are especially vital in 
determining the selectivity according to the robust linear models. The use of multiple crystallographic 
proteins in the docking study should further improve the docking accuracy and be helpful for to the 
efficient identification of potential pharmacological groups. Hydrogen bond interactions form the base 
of the favorable interaction of ligands with both ERα and ERβ, but the binding affinity strength is 
more correlated with the atom fragment type, polarizabilities, electronegativites and hydrophobicity. 
Compound22 and compound10 are the most ERβ selective compounds, as the docking results show Int. J. Mol. Sci. 2010, 11                       
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that the spatial orientations of naphthalene or the quinoline plane and the substituent in position 8 are 
most  correlated  with  the  ER  subtype  selectivity.  However,  the  top  ranking  pose  scores  failed  to 
correlate precisely with pIC50 in each case with R
2 < 0.2. Thus, it is difficult to determine the binding 
affinity  of  ER  ligands  only  by  the  docking  scores.  Our  results  demonstrate  the  applicability  and 
adaptability of the QSAR models and the necessity of performing docking processes using multiple 
crystallographic proteins to accurately screen and discover potential ER subtype selective ligands.  
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